{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-011867","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.724749+00:00","generated_at":"2026-05-17T14:11:08.869060+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aspira Women's Health Q2 revenue stable at $2.4M; H1 gross margin improves to 66.1%","bullets":["Q2 product revenue $2.404M vs $2.423M YoY; commercial portfolio AUP up 12%.","H1 2025 revenue $4.683M (+2.3% YoY); gross margin 66.1% (vs 57.6% in H1 2024).","Operating expenses down 31% to $8.1M; cash burn reduced 41% to $4.8M in H1.","Sales force cut from 19 to 7 FTEs; sales per FTE up 156% in Q2.","CEO Mike Buhle reaffirms ENDOInform milestone completion by end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-011867","json":"https://secwatch.observer/filing/0001493152-25-011867.json","markdown":"https://secwatch.observer/filing/0001493152-25-011867.md","text":"https://secwatch.observer/filing/0001493152-25-011867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000149315225011867/0001493152-25-011867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000149315225011867/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:11:08.869060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}